Hypometabolism, characterized by decreased brain glucose consumption, is a common feature of many neurodegenerative diseases. Initial hypometabolic brain state, created by characteristic risk factors, may predispose the brain to acquired epilepsy and sporadic Alzheimer's and Parkinson's diseases, which are the focus of this review. Analysis of available data suggests that deficient glucose metabolism is likely a primary initiating factor for these diseases, and that resulting neuronal dysfunction further promotes the metabolic imbalance, establishing an effective positive feedback loop and a downward spiral of disease progression. Therefore, metabolic correction leading to the normalization of abnormalities in glucose metabolism may be an efficient tool to treat the neurological disorders by counteracting their primary pathological mechanisms. Published and preliminary experimental results on this approach for treating Alzheimer's disease and epilepsy models support the efficacy of metabolic correction, confirming the highly promising nature of the strategy. V C 2017 Wiley Periodicals, Inc.
More than 600 disorders affect the human nervous system; neurodegenerative diseases are characterized by progressive nervous system dysfunction and can be both hereditary and sporadic. They are often associated with atrophy of the affected brain structures and include disorders such as Alzheimer's disease and other dementias, degenerative nerve diseases, epilepsy, Parkinson's disease, multiple sclerosis, Huntington's disease, and others. Most, if not all, neurodegenerative diseases are still poorly understood and lack effective treatments or cures.
In this review, we will primarily focus on the results from studies on acquired epilepsy (AE) and sporadic Alzheimer's and Parkinson's diseases (AD; PD) suggesting that these progressive pathologies share common or interacting pathways at their early phase, although the specific mechanisms underlying the initiation of each particular disease are yet unclear. Our analysis led to a hypothesis that these disorders stem from metabolic dysfunctions-as a consequence of various risk factors-and progress by accelerating through metabolism-associated positive feedback loops that lead to a downward spiral of neurodegeneration. Moreover, it appears that deficient glucose metabolism may be a primary initiation trigger for the diseases; therefore, we propose the metabolic correction as an efficient way for counteracting these pathologies.
Short Outline of Main Glucose Functions
Glycolysis provides 2 ATP molecules per one glucose molecule (independent of oxygen), while mitochondria produce 34 ATP, leading to the immediate (and correct) conclusion that mitochondria are much more efficient in energy production. However, a consequent conclusion that glycolysis is therefore just a fuel supplier (via pyruvate or lactate) for mitochondria may be very misleading. This is because the glycolytic rate can be 10-100 times faster than that of mitochondrial processing. Thus, although inefficient, glycolysis can potentially generate substantial amounts of available ATP (Dienel and Cruz, 2016; Epstein et al., 2014; Raichle, 2015) . Indeed, high levels of brain tissue lactate correlated with brain activity can be a consequence of situation when only a part of pyruvate goes to the Krebs cycle while the remainder is transformed to lactate and exported out of the cell. Such process has been called "aerobic glycolysis," as the lactate production proceeds despite the presence of oxygen (Liberti and Locasale, 2016) . Aerobic glycolysis (or Warburg effect) is a characteristic feature of cancer cells, which for some reason prefer to produce energy by strongly enhancing the glycolytic rate. However, it is very likely that aerobic glycolysis is not a pathogenic feature but instead a normal physiological property of cell metabolism employed when fast energy production is required (Dienel and Cruz, 2016; Epstein et al., 2014; Raichle, 2015) .
There are several cell types for which aerobic glycolysis is well documented. For instance, endothelial cells get about 85% of their energy from glycolytic ATP (Ghesquiere et al., 2014) ; fast-twitch muscle fibers get most energy from glycolysis (Schmitz et al., 2013) ; activated microglia utilize glycolytic ATP (Voloboueva et al., 2013) ; and finally, in humans it has been convincingly shown that during brain activation by learning-associated tasks there is a significant increase in aerobic glycolysis without a change (or even with a decrease) in oxygen consumption (Madsen et al., 1995; Shannon et al., 2016) . Regarding glucose metabolism, this scenario suggests the existence of two ATP generators in a cell: glycolytic provides rapid energy during acute energy demands, presumably mostly for the membrane-associated processes such as K 1 /Na 1 -ATPase (Fernandez-Moncada and Barros, 2014; Glitsch and Tappe, 1993; Silver and Erecinska, 1997) and Ca 21 -ATPase (Kahlert and Reiser, 2000; Xu et al., 1995) , while mitochondria-produced ATP supports all basal/homeostatic cellular energy needs (Epstein et al., 2014) . Interestingly, the function of GABAA receptors is maintained by endogenous phosphorylation (Pumain et al., 2008) and it was found in both rat (Laschet et al., 2004) and human (Laschet et al., 2007) neurons that the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is closely associated in the membrane with the receptor and phosphorylates its a1 subunit. These findings suggest that functioning of GABAA receptors and, therefore, the locally produced glycolytic ATP supports neuronal inhibition. Notably, as a primary substrate for glycolysis, only glucose-and no other (e.g., utilized by mitochondria) endogenous energy substratescan support the rapid energy delivery.
Another very important molecular pathway of glucose metabolism is the pentose phosphate pathway (PPP), which is parallel to glycolysis (Stincone et al., 2015) . It generates NADPH, which provides the redox power for antioxidant systems and pentoses (5-carbon sugars; e.g., ribose 5-phosphate that is a precursor for synthesis of nucleotides). Thus, PPP has two major functions, biosynthesis and defense against free radicals. Oxidative stress occurs as a consequence of accumulation of reactive oxygen (ROS) and nitrogen (RNS) species. Physiological concentrations ROS/RNS play a major role in different processes, including signalling pathways, the induction of mitogenic response, and the defense against infectious pathogens (Rhee, 2006) . However, their overproduction and failure of endogenous antioxidant defenses lead to oxidative damage, including post-translational modification and the oxidation of proteins as well as the oxidation of lipids and DNA/RNA, which are the common features of many neurodegenerative diseases (Bhat et al., 2015) .
ROS include nonorganic molecules such as superoxide radical anion (O 2-), hydrogen peroxide (H 2 O 2 ), and hydroxylradical (HO -). Superoxide is continuously generated in the mitochondrial respiration chain and thereafter, converted to H 2 O 2 , can penetrate through the mitochondria membrane into the cytoplasm. Another source of ROS in cytoplasm is NADPH oxidase (NOX), which is expressed in both the outer cell and endoplasmic reticulum membranes (Brennan et al., 2009; Cahill-Smith and Li, 2014; Demaurex and Scorrano, 2009 . ROS are extremely chemically active free radicals and can cause wide-ranging damage to macromolecules. Since oxidation of proteins and metabolites occurs virtually instantaneously, immediate cellular countermeasures are crucial for combating the negative effects of acute oxidative stress. The fastest known cellular response to oxidative stress is provided by up-regulation of the pentose phosphate pathway (Dick and Ralser, 2015) . It has been demonstrated that oxidants induce the inactivation of glycolytic enzymes, in particular of glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Butterfield et al., 2010; Hildebrandt et al., 2015) , and inhibition of glycolysis that may result in re-distribution of metabolic fluxes in favor of PPP activation (Butterfield et al., 2010; Ralser et al., 2007; Ralser et al., 2009) . Oxidative stress can also cause DNA damage leading to over-activation of Poly(ADP-ribose) polymerase-1 (PARP-1), a sensor of oxidative DNA damage, which in turn results in extensive consumption and depletion of NAD 1 and the inhibition of glycolysis (Smith et al., 2013) . Thus, oxidative stress results in inhibition of glycolysis and the activation of the PPP antioxidant defense system. Furthermore, increased flux into PPP provides the building blocks for de novo biosynthesis of nucleotides, necessary for ROS-induced DNA damage repair.
In summary, in addition to supplying the mitochondrial fuel, glucose metabolism provides (a) biosynthesis, (b) cytoplasmic antioxidant defense, and (c) fast energy production. Glucose is indispensable for all of these functions.
Risk Factors and Common Disease Pathological Features
Major preconditioning risk factors such as cardiovascular dysfunction, diabetes, metabolic syndrome, traumatic brain injury, and stroke are shared by the sporadic AD (Biessels and Reagan, 2015; Chakrabarti et al., 2015; de la Torre, 2012; Patterson et al., 2007) and PD (Athauda and Foltynie 2016; Daneshvar et al., 2015; Jabir et al., 2015; Jha et al., 2016; Santiago and Potashkin, 2013; Santiago and Potashkin, 2014) , in addition to being associated with AE (Chou et al., 2016; Kalra et al., 2016; Ono and Galanopoulou, 2012; Pitkanen et al., 2015; Verrotti et al., 2012; Waldbaum and Patel, 2010b) . These factors are characterized by common brain pathologies such as chronic hypoperfusion (Scholz and Hanefeld, 2016; Zlokovic, 2011) , neuro-inflammation, and insulin resistance (Rosales-Corral et al., 2015; Straub 2014; Yamagata et al., 2017) , all leading to energy deficiency and oxidative stress. At the same time, the major genetic risk factors for sporadic AD, APOE e4 allele Zlokovic, 2013) , and TREM2 mutations (Guerreiro et al., 2013; Jonsson et al., 2013) , and a-synuclein gene, MAPT, LRRK2, and GBA for PD (Deleidi and Gasser, 2013; Kalinderi et al., 2016 ) also lead to neurovascular dysfunction and neuro-inflammation. Downstream molecular outcomes of these pathologies are, in particular: for AD, the upregulation of beta-secretase 1 (BACE1), amyloidbeta (Ab) overproduction (Cirrito et al., 2008; Koike et al., 2010; O'Connor et al., 2008; Sun et al., 2006; Tamagno et al., 2012; Velliquette et al., 2005; Zhao et al., 2011) , as well as promotion of tauopathy (Lauretti et al., 2017) ; and accumulation and aggregation of alphasynuclein in PD (Athauda and Foltynie, 2016; Jiang et al., 2016) -suggesting that energy deficiency precedes toxic peptide overproduction so commonly thought as the defining pathology for these diseases, with its resulting neurotoxicity.
The specific cause of sporadic AD and PD is unknown, with currently available drug treatments providing at most a symptomatic relief and not a cure. A number of known underlying risk factors led to a number of various hypotheses on the cause of the disease. In AD, for instance, such main hypotheses are genetic inheritance , the cholinergic hypothesis (Francis et al., 1999) , the amyloid hypothesis (Hardy, 2009; Karran et al., 2011) , the tau hypothesis (Arendt et al., 2015; Maccioni et al., 2010) , the neurovascular hypothesis (Zlokovic, 2011) , and others. The wide diversity of causes and manifestations of the disease development resulted in an increasingly popular view that each of these disorders represents not a single disease but rather a syndrome (Blass, 2000; Dexter and Jenner, 2013; Khachaturian et al., 2016; Korczyn and Hassin-Baer, 2015) , in analogy to the metabolic syndrome (Scholz and Hanefeld, 2016; Sperling et al., 2015) . However, analysis of the risk factors shared among these diseases reveals that disrupted glucose metabolism associated with oxidative stress and neuroinflammation is the common end state of most, if not all, risk factors preceding the neurodegenerative disease initiation. If one considers this (pre-) pathological condition as the initiation state for the disease and the driver of its progression, it becomes evident that the subsequent particular pathogenesis then depends on a number of parameters (genetic and phenotypic differences) specific for each individual patient-and therefore results in a specific pathological phenotype of each neurodegenerative disease.
Thus, as the result of common risk factors AE, sporadic AD, and PD share many of the common pathological hallmarks in the early stages. The most important of these traits are outlined below.
Reduced Glucose Utilization
AD. The quantitative evaluation of reduced glucose metabolism in the AD brain was first performed by arterio-venous difference studies 20-30 years ago (Hoyer et al., 1988; Lying-Tunell et al., 1981; Ogawa et al., 1996) . Decades of research using FDG-PET imaging have clearly shown that regional brain glucose metabolism is deficient in AD. Moreover, studies have shown that glucose hypometabolism is present well before any measurable cognitive dysfunction or AD-specific pathological alterations and therefore represents the early presymptomatic signature of AD development (Chen and Zhong, 2013; Costantini et al., 2008; Cunnane et al., 2011; Cunnane et al., 2016a) . In fact, regional glucose hypometabolism in non-AD MCI patients was an accurate predictor of individual outcomes-whether they would progress to AD or not ( Fig. 1A ; Drzezga et al., 2003; Mosconi et al., 2008) .
In hippocampal slices, protofibrillar Ab 1-42 induced a strong reduction of glucose uptake seen as abated activity-dependent extracellular glucose transients (Ivanov et al., 2016) , as well as significantly decreased NAD(P)H response overshoot (upper part of biphasic fluorescence response to synaptic stimulation; Ivanov et al., 2016; Zilberter et al., 2013) presumably directly related to glycolysis (Ivanov et al., 2014) . Interestingly, however, neither NAD(P)H nor FAD oxidative phase representing mitochondrial processing, nor oxygen consumption changed under Ab 1-42 (Ivanov et al., 2016; Zilberter et al., 2013) . These results indicate impaired glycolysis but an intact mitochondrial function.
PD. PD patients, even at the early stage, exhibit widespread cortical hypoperfusion and hypometabolism (i.e., reduced glucose consumption; Fig. 1D ; Berti et al., 2012; Borghammer, 2012; Borghammer et al., 2010; Dunn et al., 2014; Xu et al., 2015) . Similar to presymptomatic AD, the low levels of CMR Glc in the frontal lobes and the caudate putamen are good predictors for the severity and progression of PD and may precede the clinical manifestation of the disease (Xu et al., 2015) . Importantly, most of the reported regional metabolic and functional abnormalities occur at early stages of PD that are not accompanied by Lewy pathology (Ferrer, 2009 ).
AE. While seizures are certainly paralleled by increased brain glucose metabolism and oxygen consumption due to highly increased network activity (Chapman et al., 1977; Duffy et al., 1975; Howse et al., 1974) , decreased glucose utilization during quiescent (interictal) periods, detected using FDG-PET imaging, is a widely recognized biomarker for human epilepsy ( Fig. 1B ; Pan et al., 2008; Pittau et al., 2014) . Interestingly, a similar technique used in a number of different animal models revealed that hypometabolism, indicated by reduced glucose consumption, is a very early sign of epileptogenesis (Bascunana et al., 2016; Goffin et al., 2009; Guo et al., 2009; Jupp et al., 2012; Lee et al., 2012; Zhang et al., 2015) . In very severe epilepsy models like pilocarpine-or kainate-induced, where epileptogenesis is initiated via status epilepticus, significant glucose utilization deficiency has been detected in the latent period (Fig. 1C) -a "quiescent" time gap (about 2-3 weeks) between the initial status epilepticus and the appearance of recurrent seizures (Goffin et al., 2009; Guo et al., 2009; Lee et al., 2012; Zhang et al., 2015) . FDG-PET imaging in another popular epilepsy model (PTZ-kindling) also showed that animals with successful kindling (i.e., epileptic) all showed significant reductions of glucose utilization in multiple Fig. 1 . Reduced glucose utilization in early stages of neurodegenerative diseases.(A) Regional reductions (compared to healthy controls) in cerebral glucose metabolic rate (CMRglc) observed using positron emission tomography with FDG-PET: in AD patients (AD, top), patients with mild cognitive impairment (MCI) that progressed to AD after 2 years (MCI-AD, middle), and in MCI patients who remained stable (MCI-MCI, bottom). Z-score represents deviation from normal. Adapted and modified from (Mosconi et al., 2008) . (B) An FDG-PET study in a patient with an epileptogenic focus in the left temporal lobe. The scan shows widespread hypometabolism in this lobe, more extensive than that in the epileptogenic focus alone (Warwick, 2013) .
(C) CMRglc images in pilocarpine-induced rat model of temporal lobe epilepsy showing glucose metabolism in baseline control (top), with reductions in glucose metabolism during both early and latent "quiet" periods following the kindling, with subsequent chronic epilepsy development (bottom). Adapted and modified from (Guo et al., 2009) 
. (D) Pronounced reduction in glucose metabolism in de novo
Parkinson's disease patients compared to normal control subjects. The image data was scaled using white matter (WM) normalization, with t-values representing significance of deviation from normal. Adapted and modified from (Berti et al., 2012). brain regions, while animals with "unsuccessful" kindling (i.e., those avoiding the epileptic state) all exhibited normal glucose metabolism (Bascunana et al., 2016) . Importantly, this hypometabolism was not correlated with the MRI-detected atrophy or pyramidal cell loss (Bascunana et al., 2016; Jupp et al., 2012) , confirming that the initial stage of epileptogenesis is directly associated with the glucose metabolism dysfunction.
The question of principal importance, one that has not yet been conclusively answered, is whether brain hypometabolism is simply a consequence of epilepsy or is itself an initiating and driving factor for epileptogenesis. To address this question by utilizing a glucose analogue 2-deoxy-D-glycose (2-DG), we explored the effects of acute inhibition of glycolysis in brain slices and the chronic effects of such inhibition in-vivo (Samokhina et al., 2017 ; see also Bachelard, 1971; Bachelard et al., 1971) . We found that in slices, 2-DG induced synaptic dysfunction while at the same time increasing postsynaptic excitability (seen as a significant depolarization of both the neuronal resting membrane potential, E m , and GABA-mediated current reversal potential, E GABA ). To clarify the long-term consequences of these effects in vivo, we recorded brain activity in freely moving rats prior to and following chronic glycolysis inhibition via daily intracerebroventricular 2-DG injections. We found that the resulting impaired brain glucose consumption led to the initiation of paroxysmal brain activity resembling epileptogenesis; some treated rats actually developed tonic-clonic seizures. These results suggest that glucose hypometabolism alone can initiate epilepsy.
To elucidate the other side of this chicken-or-egg question-whether the seizures are capable of lasting disruption of energy metabolism and network excitabilitywe developed a "seizure model" in hippocampal slices and evaluated the resting-state network and energy parameters following the recovery from seizures (Ivanov et al., 2016) . We found that a few seizures strongly compromised the energy metabolism of the neuronal network; a phenomenon associated with accumulation of ROS (see also: Azam et al., 2012; Martinc et al., 2012) and significantly reduced glucose utilization. These effects were long lasting, at least two hours after the last seizure. Metabolic dysfunction induced by seizures was also evidenced by a strongly decreased NAD(P)H overshoot as well as a decreased FAD undershoot in response to synaptic stimulation, indicating inhibited glycolysis (Ivanov et al., 2014) and similar to what we have observed after Ab application. Similar changes in the NAD(P)H overshoot have also been previously reported in hippocampal slices from pilocarpine-treated, chronic epileptic rats and from pharmaco-resistant epileptic patients (Kann et al., 2005) . Interestingly, mitochondrial oxidative metabolism seemed to remain unaltered as the NAD(P)H and FAD oxidation phases as well as oxygen consumption did not change following the seizures (Ivanov et al., 2016) . Thus, the seizures' effect on glucose consumption is rapid and long lasting, likely associated with oxidative stress-and more importantly, is potentially reversible since the reduced glucose consumption following the seizures (as in the case of Ab effects) was completely restored by subsequent application of pyruvate (Ivanov et al., 2016) . Interestingly, neither lactate nor b-hydroxybutyrate could reproduce this pyruvate effect.
Neuro-inflammation AD. Neuro-inflammation is an early and consistent feature of AD. Increasing evidence suggests that Alzheimer's disease pathogenesis includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to microglia and astroglia and trigger an innate immune response characterized by release of inflammatory mediators, which contribute to disease progression and severity (Heneka et al., 2015) . Since chronic inflammation is known to exacerbate insulin resistance associated with systemic disease-states, neuro-inflammation could also have an important role in the brain insulin and insulin-like growth factor-1 (IGF-1) resistances that occur in AD and PD (de la Monte, 2017; Tong et al., 2009 ).
PD. Inflammation occurs at multiple levels in both sporadic and familial PD, and recent data from epidemiological, genetic, and functional studies support the key role of inflammatory responses in the initiation and progression of disease pathology. The emerging hypothesis is that inflammation may even precede the onset of PD. Indeed, transgenic animal models of PD show that inflammation is an early event that can even precede neurodegeneration (Chung et al., 2009 ). Inflammation, induced by cytokines released from activated microglia and astrocytes, alters synaptic transmission and axonal transport and increases neuronal susceptibility to subsequent neurotoxic insults. The presence of microglial activation and reactive astrogliosis as well as elevated several pro-inflammatory cytokines and chemokines were reported in several post-mortem studies of PD patients (De Virgilio et al., 2016; Deleidi and Gasser, 2013; Hirsch and Hunot, 2009; Niranjan, 2014) .
AE. Chronic inflammatory processes within the brain often cause neurotoxicity and hyperexcitability. Mounting evidence points to a mutual facilitation between inflammation and epilepsy (Dey et al., 2016; Webster et al., 2017; Wilcox and Vezzani, 2014) . In general, initial prolonged seizures can trigger acute immune and inflammatory responses within the brain, while the subsequent spontaneous recurrent seizures sustain the chronic neuro-inflammation. An increasing body of clinical and preclinical evidence points to the involvement of inflammation in the pathophysiology of acute brain insults and subsequent epileptogenesis (de Vries et al., 2016; Dey et al., 2016) . A recent study has shown that acute inflammatory response rapidly induces neuronal hyperexcitability and resulting epileptiform activity in brain slices (Tzour et al., 2017) .
Insulin Resistance
Insulin resistance and disruption of insulindependent signalling pathways is a common feature of AD (Biessels and Reagan, 2015; De Felice et al., 2014; de la Monte, 2017; de la Monte and Tong, 2014; Xie et al., 2002) and PD (Athauda and Foltynie, 2016; AvilesOlmos et al., 2013; Santiago and Potashkin, 2014) . It is clear that inflammation and insulin resistance may exert a reciprocal relationship. On the one hand, insulin resistance may induce production of pro-inflammatory cytokines leading to cell death, while also further reducing insulin sensitivity by feedback inhibition of the insulin receptor. Simultaneously, through a feed-forward mechanism, inflammation induces mitochondrial dysfunction, driving the overproduction of reactive oxygen species to further the inflammatory state, thus enhancing neurodegeneration.
AD. In AD, brain insulin resistance is a major pathology (Biessels and Reagan, 2015; De Felice et al., 2014; de la Monte and Tong, 2014; Xie et al., 2002) presumably directly induced by Ab (Duarte et al., 2012; Hoyer, 2004; Pearson-Leary and McNay, 2012; Xie et al., 2002) . Insulin signalling regulates structural and functional aspects of synapses (Calvo-Ochoa and Arias, 2015) . By mediating vascular properties, insulin signalling also plays an important role in glucose (McEwen and Reagan, 2004) and oxygen availability to the brain (Aulston et al., 2013; Bedse et al., 2015) . Insulin signalling affects Ab production (Phiel et al., 2003) as well as its clearance toward the blood (Vandal et al., 2014) , and negatively regulates GSK-3 de la Monte and Tong, 2014; Fernandez and Torres-Aleman, 2012 ) that directly phosphorylates tau (Mandelkow et al., 2003; Reddy, 2011) . Insulin also blocks Ab binding to synapses, thereby preventing the ensuing neurotoxicity (De Felice et al., 2009; Xie et al., 2002) and Ab-induced loss of insulin receptors from neuronal dendrites (De Felice et al., 2009) .
In many reviews focusing on insulin resistance in the AD brain, the important role of insulin in glucose uptake is asserted (Chen and Zhong, 2013; de la Monte, 2012) although with references to only the insulinsensitive GluT4 transporters. However, although the expression of GluT4 transporters has been demonstrated (Apelt et al., 1999; El Messari et al., 1998; Fernando et al., 2008; McEwen and Reagan, 2004) , their contribution to the total glucose uptake in the brain has not been elucidated. Moreover, direct measurements on human tissue revealed no changes in GluT4 expression in AD brains as well as no change in glucose uptake by insulin administration (Talbot et al., 2012) . On the other hand, a decreased expression of GluT3 transporters has been shown (Jin et al., 2013) . GluT3 is considered to be insulin-independent, although insulin has been suggested to play a role in promoting translocation of the transporter into the membrane (Uemura and Greenlee, 2006) . It was also found that the decreased glucose uptake is correlated with the Ab load (Sadowski et al., 2004) , and that Ab interferes with glucose uptake by disrupting GluT3-containing vesicle fusion (Uemura and Greenlee, 2001) .
In line with these results, we found no effect of insulin on glucose transients in response to synaptic stimulation both in control and after detrimental action of Ab (Ivanov et al., 2016) . Using extracellular glucose sensors in hippocampal slices (synaptic stimulation caused a rapid increase in glucose uptake and metabolism, resulting in corresponding transient extracellular level decrease until diffusion from the medium could replenish the extracellular glucose levels), we directly measured the real-time activity-dependent glucose uptake in control, after Ab 1-42 application and following addition of pyruvate (5mM) or insulin (100nM) to ACSF. The Ab 1-42 application resulted in a significant (about 50%) reduction in network activity-induced glucose transients. Insulin application did not affect glucose transients when applied either in control, prior or following to Ab 1-42 application. It is therefore likely that the actions of insulin signalling in hippocampus are not associated with a direct effect on glucose uptake. In contrast to insulin, pyruvate showed a remarkable effect on glucose consumption in slices: while glucose uptake was reduced by half following Ab application, subsequent addition of 5mM pyruvate (in the continuing presence of Ab) restored it back to the initial control levels.
PD. PD and dementia with Lewy bodies (DLB) frequently overlap with AD (Adamowicz et al., 2017; Hansen et al., 1993; Tsuboi and Dickson, 2005) . For instance, in hippocampi of PD (DLB) patients, intracellular a-synuclein pathology frequently coincides with Ab and tau pathologies. This phenomenon is likely linked to brain impairments in insulin, IGF-1, and neurotrophin signalling. Significant reductions in insulin and IGF-1 signalling have been observed in both PD and DLB brains (Tong et al., 2009) . There is accumulating evidence suggesting that alpha-synuclein can interfere with normal insulin signalling via its action on inflammation and the AKT pathway that may further exacerbate alphasynuclein oligomer formation and protein aggregation (Athauda and Foltynie, 2016) .
AE. Although diabetes is an established risk factor for acquired epilepsy, there is a lack of reports showing how neural hyperactivity could influence brain insulin signalling. However, all major risk factors for acquired epilepsy result in neuro-inflammation, which is directly linked to insulin resistance (Rosales-Corral et al., 2015; Straub, 2014; Yamagata et al., 2017) . Therefore, it is likely that acquired epileptogenesis develops on the background of existing insulin resistance.
Neuronal Hyperactivity
AD. Epilepsy is a risk factor (Mackenzie and Miller, 1994; Scharfman, 2012) as well as a recognized comorbidity of AD (Chin and Scharfman, 2013; Noebels, 2011; Palop and Mucke, 2009; Vossel et al., 2013; Vossel et al., 2016) . Notably, neuronal hyperactivity is an early biomarker of AD (Amatniek et al., 2006; Busche and Konnerth, 2015; Noebels, 2011; Palop and Mucke, 2009) just as is hypometabolism. While the phenomena of hyperactivity and hypometabolism might appear mutually exclusive, they are in fact closely related under pathological conditions. As one primary example of how these are interrelated, consider the resting membrane potential (E m ), a principal neuronal parameter underlying excitability, which dictates the amount of excitatory input the neuron requires for activation. E m is determined by the cross-membrane gradient of K 1 and Na 1 ions that is mainly established by K 1 /Na 1 -ATPase, an ion pump that uses ATP to transport ions against their gradient (Rakowski et al., 1989) . ATP depletion invariably leads to membrane depolarization (Santos et al., 1996) resulting in neuronal postsynaptic hyperexcitability. However, energy deprivation also results in impaired synaptic signalling, a phenomenon that serves to decrease network excitability by reducing the excitatory transmission efficacy (although the efficacy of inhibitory transmission can also be decreased). Therefore, the net effect of hypometabolism on the network activity would depend on the interplay of parallel pre-and post-synaptic processes. One clear example of how network hyperactivity results from inhibited glucose metabolism was demonstrated by our recent study (Samokhina et al., 2017) .
It is logical to suggest that the mechanisms of AE represent a part of an early pathological phase of AD. In AD models, epileptic phenotypes have been shown for APPswe/PS1dE9 (APP/PS1) mice (Minkeviciene et al., 2009 ) as well as for other AD model mice (Busche and Konnerth, 2015; Palop and Mucke, 2009 ) with profound hyperactivity of neurons, astrocytes and microglia (Busche et al., 2008; Busche and Konnerth, 2015; Kuchibhotla et al., 2009; Palop and Mucke, 2010; Zilberter et al., 2013) .
Acute application of Ab 1-42 also induced aberrant network activity in hippocampal slices that was underlain by depolarization of both the E m and E GABA (Zilberter et al., 2013) . In the ex-vivo slices of APP/PS1 mice, we found a neuronal sub-population with significantly depolarized E m and E GABA paralleled by similar signs of impaired energy metabolism, mirroring abnormalities we observed under acute Ab 1-42 application. Evidently, ratio of glycolysis/neuronal activity remained inappropriately low in these pathologic states. As pyruvate in combination with BHB completely prevented this Ab toxicity on metabolic parameters and neuronal excitability, both in slices and after chronic dietary supplementation in-vivo, it is plausible to suggest that the Ab-induced metabolic abnormalities underlie neuronal network hyperactivity and epileptic phenotype. Thus, the initial energy shortage inevitably leads to neuronal network hyperactivity, elevating energy demand that cannot be met due to inhibited energy metabolism and therefore resulting in a yet greater energy crisis-creating a positive feedback loop and a vicious cycle of AD progression.
PD. In PD, epilepsy is considered as an uncommon comorbidity in a few available studies (Vercueil, 2006) , but also see: Son et al. (2016) . However, Parkinson's resting tremor is definitely induced by paroxysmal synchronous activity of the cerebello-thalamocortical network (Hallett, 2014; Singh et al., 2016) , is likely initiated in motor cortex (Dirkx et al., 2016) and represents a harmful example of rhythmic collective dynamics of large brain cell networks resembling the epileptic ones (Velazquez et al., 2015) .
Amyloidosis
It has been reported that senile plaques exist in approximately 10% of surgical samples from temporal lobe epilepsy cases that ranged in age from 36-61 years and did not exhibit dementia (Mackenzie and Miller, 1994) . Furthermore, the age-related incidence of plaque formation in epilepsy patients was significantly increased relative to age matched non-epileptic controls. In addition, phosphorylated tau overexpression has been reported in epileptic human brain and in animal models of epilepsy (Nagaishi et al., 2011; Yan et al., 2012) . Therefore, patients with chronic epilepsy not only develop plaques, as noted above, but can develop tangles (Scharfman, 2012) . Amyloid co-pathology is also common and deleterious in both DLB and PD (Fan et al., 2015; Gomperts et al., 2016; Petrou et al., 2015) . Indeed, these diseases often coexist with AD pathology (Adamowicz et al., 2017; Hansen et al., 1993; Tsuboi and Dickson, 2005 ) with a-Synuclein load found hippocampus and entorhinal cortex (Adamowicz et al., 2017) .
Mitochondrial Dysfunction
Given the observed reduction in glucose uptake, it is often typical for authors to infer that mitochondrial starvation or impairment is to blame. However, it is yet unclear what fraction of pyruvate produced by glycolysis is necessary for sufficient ATP generation by mitochondria. Significant basal lactate levels in acute brain slices superfused with ACSF (lactate-free, glucose-only solution) and the release of lactate in response to synaptic stimulation both ex-vivo and in-vivo indicate that a significant fraction of pyruvate is converted to lactate and extruded from cells (see Fig. 4 in [Samokhina et al., 2017] ).
Indeed, the results of multiple in vivo studies demonstrate significant lactate efflux from the brain during activity (see detailed analysis in [Dienel, 2012; Dienel, 2017] ).
Recently, an evaluation of fluxes through the major glucose-consuming pathways of cerebellar granule neurons at steady-state conditions showed that only about 62% of glucose was metabolized to pyruvate by glycolysis, and of that only 16% was utilized by mitochondria; meanwhile 46% was released as lactate (Gebril et al., 2016) . Obviously, extrapolation of these in-vitro results to the in-vivo conditions is problematic. The data does indicate however that only a fraction of glucose is metabolized to pyruvate and only a fraction of this pyruvate is actually metabolized by mitochondria. Moreover, under specific conditions (e.g., hypoglycaemia and ketogenesis) alternative substrates (e.g., ketone bodies, glutamate, and others) may be utilized for mitochondrial processing in vivo (Amaral, 2012) . Therefore, reduced glucose uptake does not necessarily represent or immediately result in mitochondrial starvation, and instead likely reflects glycolysis deficiency. Undoubtedly, chronically deteriorated glycolysis would eventually and inevitably lead to the mitochondrial impairment and energy starvation in the subsequent stages of the disease, as has been shown in multiple studies.
AD. Multiple studies considered different aspects of mitochondrial dysfunction in AD as a consequence of impaired glucose uptake and as the main factor behind the observed hypometabolism (Gibson et al., 2010; Simoncini et al., 2015) . It is not obvious, however, that this conclusion is valid in regards to the prodromal phase of AD. All of the authors agree that deficient energy metabolism is an initiating factor of sporadic AD-certainly, the risk factors inducing the early hypometaboic brain state promote the disease initiation. In all models, the mitochondrial dysfunction is considered as the primary factor responsible for the disease progression, thus becoming the main target for suggested treatment. It is thus very important to consider the very beginning of the disease and find out whether mitochondrial dysfunction parallels the decrease in glucose consumption, which is the earliest clinically detected symptom of the disease, or if there exists a time gap between these two processes. In other words, whether the glycolysis impairment precedes mitochondrial dysfunction in sporadic AD. In early studies using arterio-venous difference for evaluating metabolic parameters, a strong disproportion was found in the early-onset dementia patients: while glucose consumption decreased by up to 45%, it was not accompanied by abnormalities in oxygen consumption (Hoyer, 1992; Hoyer et al., 1988) . PET studies revealed that in the early stages of clinically manifest AD, the decrease in glucose utilization (about 50%; CMRglc) is higher than the decrease in oxygen utilization (about 20%; CMR O2 ). In later stages, the decrease in CMR glc and CMR O2 is proportional (Blass et al., 2002; Fukuyama et al., 1994) . The observation of disproportionate reductions in the CMRs of glucose and oxygen in the early stages of sporadic AD raises the question of which substrates other than glucose could be oxidized to produce ATP and to attenuate this severe energy deficit (Hoyer, 1992) . In recent reviews by Cunnane and colleagues, this question was discussed in detail (Cunnane et al., 2011; Cunnane et al., 2016b) . PET studies showed that in contrast to glucose, brain ketone bodies (KB) uptake is not significantly disrupted early on in AD (Castellano et al., 2015; Ogawa et al., 1996) . Normal KB metabolism also suggests that the enzymes of mitochondrial oxidative phosphorylation in the brain continue to function relatively normally, at least in early AD. These results are in line with a suggestion first made by Hoyer et al. (1988) that mitochondria function is relatively normal early in AD and the main initial pathology is in the glucose uptake and its metabolism by glycolysis. Our direct measurements of metabolic parameters in brain slices (see above) are also in agreement with this suggestion. Therefore, it is plausible to suggest that deficient glycolysis is the primary cause of metabolic abnormalities leading to the disease initiation, while mitochondrial dysfunction follows and is evident during subsequent pathogenesis.
PD. A large body of evidence supports a central role of mitochondria alterations in the pathogenesis of PD and suggests that mitochondrial dysfunction might be a defect that occurs early in PD pathogenesis (Subramaniam and Chesselet, 2013; Zaltieri et al., 2015) . The findings suggest that complex I deficiency and related oxidative stress in addition to mitochondrial DNA mutations are associated with PD pathogenesis. However, whether asynuclein synaptic deposition is the priming event for the onset of PD-or vice versa, that mitochondrial deficits anticipate and trigger a-synuclein pathology and dopamine neuron degeneration-is still an open question (Zaltieri et al., 2015) .
AE. In epilepsy, it has been suggested that hypometabolism is associated with mitochondrial dysfunction in neurons (Kudin et al., 2009; Pan et al., 2008 ; Waldbaum and Patel 2010a) presumably as a consequence of deficient glycolysis. As in sporadic AD, mitochondrial dysfunction has mainly been proposed to be responsible for the initiation of pathogenic process (Otahal et al., 2014; Puttachary et al., 2015; Rowley and Patel, 2013; Waldbaum and Patel, 2010b; Zsurka and Kunz, 2015) . There is no doubt that mitochondrial abnormalities play a key role in epileptogenesis as has been shown in many studies. However, in analogy with the prodromal AD, it is likely that mitochondrial dysfunction is preceded by the dysfunction of glycolysis. It has been shown recently by in vivo microdialysis in rats that despite the strong oxidative stress and metabolic disturbances due to status epilepticus, mitochondrial function remained normal for at least 90 minutes following seizures (Imran et al., 2015) .
Oxidative Stress
Oxidative stress is a prominent feature in AD (Abeti and Duchen, 2012; Cahill-Smith and Li, 2014; Moreira et al., 2009) , PD Subramaniam and Chesselet, 2013; Yan et al., 2013) , and AE (Aguiar et al., 2012; Puttachary et al., 2015; Rowley and Patel, 2013) . Oxidative stress is also linked with the development of neuronal death and neural dysfunction, which suggests its key pathogenic role in these diseases. There may exist multiple sources of free radicals that induce oxidative stress, including mitochondrial dysfunction, inflammation, impaired glucose metabolism, misfolded protein toxicity, and others.
Importantly, all brain pathologies listed above are strongly interconnected and create a solid background for further disease progression. As was noted by John P. Blass (Blass 2001 ) "Deficiencies in all the major pathways of oxidative/energy metabolism have been found in patients with brain diseases (Table I ). Many of the most common and important diseases of the brain have been found to be associated with deficiencies in these pathways (Table II) " (see corresponding tables in his review). Metabolic abnormalities associated with neurological diseases provided the background for the hypothesis of metabolic origin of neurodegenerative diseases, specifically the sporadic AD (Blass, 2000; Demetrius and Driver, 2013; Grimm et al., 2016; Hoyer, 2000; Saxena, 2011; Swerdlow et al., 2014) . If we accept this hypothesis, then metabolic correction may be the most efficient treatment.
Ketogenic Diet-the Only Clinically Accepted Metabolic Treatment
To date, the only widely clinically accepted metabolic treatment for epilepsy is the ketogenic diet (KD). This diet proved efficient for treating intractable pediatric epilepsy (Kossoff and Hartman, 2012; Maalouf et al., 2009) . In KD, low-carb, high-fat nutrition leads to a high blood concentration of ketone bodies that can affect brain energy metabolism by partially substituting glucose (Bough and Rho, 2007) . The exact mechanisms of the diet's antiepileptic action are still not known and multiple hypotheses on possible molecular pathways can be found in several detailed reviews (see [Danial et al., 2013; Masino and Rho, 2012; Rho, 2015; Rogawski et al., 2016] ). The efficacy of KD and the hypotheses of its underlying mechanisms led to research attempting to replicate its core therapeutic benefits. Some studies thus focused on the potential anti-epileptic role of glycolysis inhibition (Garriga-Canut et al., 2006; Sada et al., 2015; Stafstrom et al., 2009 ) without taking into account the crucial fact that glycolysis inhibition without compensation inevitably leads to energy deprivation, while in the KD where glucose is substituted by ketone bodies, energy depletion does not occur. It is unlikely that such a suppression of energy supply contributes to the observed anti-epileptic action of KD as has been suggested, since ATP synthesis was reported to be normal or increased during KD (Maalouf et al., 2009 ) while ATP levels in brain tissue either remained unchanged (Bough et al., 2006; Nylen et al., 2009 ) or increased (DeVivo et al., 1978 Nakazawa et al., 1983) . The high oxidative capacity for glucose during KD irrespective of ketotic or nonketotic state was reported (Zhang et al., 2013a) . Regarding the cerebral glucose metabolic rate, it was found to be either decreased (Zhang et al., 2013b ), unchanged (al-Mudallal et al., 1995 or increased (Roy et al., 2012) . We conclude that even if there is some reduction in glycolysis during KD due to a partial substitution of glucose by ketone bodies for mitochondrial fuelling, it should not be considered as associated with an overall inhibition of energy metabolism. Moreover, our results (Samokhina et al., 2017) demonstrate that chronic inhibition of energy metabolism would only further aggravate the metabolic crisis already established during epileptogenesis (Jupp et al., 2012; Kudin et al., 2009; Lee et al., 2012; Reid et al., 2014) , as this inhibition alone was sufficient to initiate epileptiform activity in initially healthy rats. It is also possible that the use of ketone bodies in KD for oxidative metabolism "frees up" glucose for other important functions such as cytoplasmic antioxidant defense system (Stincone et al., 2015) . One interesting approach is the administration of fatty acids, such as triheptanoin, to mimic the effects of KD, having showed promising results (Borges and Sonnewald, 2012) .
The ketogenic diet has also been used with moderate effect in patients suffering from AD (Cunnane et al., 2016b; Hertz et al., 2015) . In adults, however, the diet's mainstream use is still limited due to multiple complications such as malnutrition, poor compliance, and adverse effects: impaired myocardial function, metabolic abnormalities such as hyperuricemia, decreased amino acid levels, acidosis and mineral imbalance (Hallbook et al., 2011; Kossoff et al., 2009; Payne et al., 2011; Vaccarezza and Silva, 2015) . Additional concerns have been raised as the diet induces a rise in cholesterol levels and is also associated with potential risks of visceral fat accumulation, increased fat mass in turn leading to glucose intolerance, and may thus increase the risk of a metabolic syndrome (Kang et al., 2004; Keene, 2006; Ribeiro et al., 2008) .
The Concept of Metabolic Correction as Treatment
We hypothesized that the primary pathways of disease progression start from the initial glucose metabolism deficiency and oxidative stress created by the associated risk factors, are potentiated within positive feedback loops, and result in greater metabolic deficiency and oxidative stress, thus creating the vicious cycle of disease development (Fig. 2) .
Here, the deficiency in glucose metabolism associated with oxidative stress and neuro-inflammation is a trigger and driving force for AE, sporadic AD and PD.
We selected pyruvate as a primary component for metabolic correction due to its unique set of neuroprotective properties (for review, see [Zilberter et al., 2015b] ). Pyruvate is (1) the main mitochondrial fuel provider; and (2) potent ROS scavenger/antioxidant, specifically efficient against hydrogen peroxide (Das, 2006; Desagher et al., 1997) . It also (3) prevents over activation of PARP-1 (Martire et al., 2015; Wang et al., 2015) , leading to a depletion of cytoplasmic NAD 1 (Kovac et al., 2013; Mongan et al., 2003; Ying et al., 2002) and the inhibition of hexokinase (Andrabi et al., 2014) , followed by inhibition of glycolysis and ATP production; (4) facilitates glutamate efflux from the brain, reducing neurotoxicity (Gottlieb et al., 2003; Zlotnik et al., 2008; Zlotnik et al., 2012) ; (5) augments glycogen stores in the brain (Koivisto et al., 2016; Shetty et al., 2012) ; (6) acts antiinflammatory (Das, 2006; Kao and Fink, 2010) ; and (7) prevents neuronal hyperexcitability (Isopi et al., 2014; Simeone et al., 2014; Zilberter et al., 2013) .
In our initial study (Zilberter et al., 2013) , we showed that administration of exogenous oxidative energy substrates (combination of pyruvate and 3-b hydroxybutyrate, BHB) reduced the Ab-induced abnormal neuronal activity ex vivo and the epileptic phenotype in APP/PS1 mice in vivo. In a subsequent study, similar results have been obtained with administration of pyruvate alone (Zilberter et al., 2015a) , indicating that the pyruvate exerts the dominant effect: chronic dietary supplementation of pyruvate to APP/PS1 mice displaying AD-related epilepsy phenotype (Minkeviciene et al., 2009 ) prevented neural hyperactivity in vivo. In wildtype slices, acute application of protofibrillar Ab 1-42 induced aberrant network activity in hippocampus that was underlain by depolarization of both the E m and E GABA . These changes were paralleled by clear indications of impaired energy metabolism. However, when glucose was supplemented with pyruvate in ACSF, Ab 1-42 failed to induce detrimental changes in any of the above parameters. Importantly, Ab 1-42 strongly impaired neuronal long-term potentiation (LTP), an effect that was absent in the presence of pyruvate. While all of the acute Ab effects were also seen in ex-vivo slices from APP/PS1 animals, none of these dysfunctions were observed in transgenic mice that were fed the pyruvate-enriched diet. We further showed that following the Ab application, energy metabolism of the neuronal network is compromised (Zilberter et al., 2013) , a phenomenon associated with accumulation of ROS (see also: Abeti and Duchen, 2012; Abramov and Duchen, 2005; Azam et al., 2012; De Felice et al., 2007; Martinc et al., 2012) and strongly reduced glucose utilization (Ivanov et al., 2016) . Interestingly, the Ab effects on glucose consumption and metabolism look very similar to those produced by seizures, pointing to oxidative stress as one likely underlying cause. Subsequent addition of pyruvate induced a significant increase in glucose uptake. Similar normalizing effects of pyruvate were observed on energy metabolism and glucose uptake disruptions induced by seizures (Ivanov et al., 2016) .
Altogether, our results suggest that early AD-related neuronal malfunctions underlying hyperexcitability can be prevented by chronic administration of pyruvate (Zilberter et al., 2015a) .
Possible Reasons for the Seizure-or Ab-induced Reduced Glucose Uptake and the Restorative Effect Of Pyruvate
Since ROS directly and indirectly affect its structure and function, oxidative stress associated with seizures, Ab and a-Syn action induces inactivation of GAPDH (Butterfield et al., 2010) . GAPDH contains binding domains for NAD 1 (a coenzyme) and for glyceraldehyde-3-phosphate (G3P). GAPDH is most known for its role in glycolysis, catalyzing the reversible phosphorylation of G3P to 1,3-bisphosphoglycerate, reducing NAD 1 as a cofactor to NADH. However, when GAPDH glycolytic activity is impeded, G3P accumulates and (via dihydroxyacetone phosphate) gives rise to the deleterious breakdown product, methylglyoxal-a highly reactive a-ketoaldehyde that readily oxidizes proteins, lipids, and other cellular components, leading to cytotoxicity (Allaman et al., 2015) and therefore possibly playing a significant role in neurodegeneration. It was reported (Ahmed et al., 2005) that in cerebrospinal fluid of AD patients, the concentration of methylglyoxal-derived hydroimidazolone, compared to age-matched controls, was increased 30-fold. It should be noted that besides being involved in glucose metabolism, GAPDH has other functions; during oxidative stress it can be translocated to various subcellular organelles (e.g., nucleus) and contribute to cell death/dysfunction (see : Sirover, 2014; Tristan et al., 2011) .
Presumably as a self-protective antioxidant mechanism, the inhibition of GAPDH would cause the cell to shift its reliance on glycolysis to the pentose phosphate shunt (Dick and Ralser, 2015; Ralser et al., 2007) . However, this antioxidant defense is eventually overcome in the progression of neurodegenerative disease by the everincreasing amount of free radicals generated in the sick brain. Oxidative stress also results in over-activation of PARP-1 with the subsequent depletion of NAD 1 (Abeti and Duchen, 2012; Smith et al., 2013) that also leads to inactivation of GAPDH function. Altogether, oxidative stress inactivates glycolysis, consequently resulting in a decreased glucose uptake. We suggest that one main factor in the exogenous pyruvate's restorative effect is its ability to reinstate the cytoplasmic level of NAD 1 . Pyruvate accomplishes this via at least two pathways; (1) a conversion to lactate by lactate-dehydrogenase with oxidation of NADH to NAD 1 ; and (2) prevention of PARP-1 over-activation (Abeti et al., 2011) . In addition, pyruvate as an efficient antioxidant can neutralize, at least in part, the remaining oxidative stress. All these effects result in an enhancement of GAPDH and glycolysis activity, followed by an increase in glucose consumption.
Potential Involvement of Glucose Transporters
Reduced concentration of glucose transporters GLUT3 and GLUT1 have been reported in AD brains (Harr et al., 1995; Mooradian et al., 1997; Simpson et al., 1994) , suggesting another potential mechanism of glucose utilization inhibition in AD. Ab has been reported to impair glucose uptake by interfering with exocytosisdependent GLUT3 membrane expression (Prapong et al., 2002; Uemura and Greenlee, 2001 ; although parallel Abinduced increase in GLUT3 mRNA transcription was also shown; Prapong et al., 2002) . GLUT3 membrane expression is regulated by AMP-activated protein kinase (AMPK; Weisova et al., 2009) , and it was shown that Ab inhibits AMPK activity .
Links between oxidative stress and glucose transporter function have also been reported. Ab was shown to interfere with GLUT3 function through lipid peroxidation. In rat cultured neurons, Ab induced conjugation of 4-hydroxynonenal (HNE, an aldehydic product of lipid peroxidation) to GLUT3, inhibiting its function and leading to ATP depletion (Mark et al., 1997) . Recorded significant oxidative stress induced by seizure activity in slices may also result in HNE production and downstream GLUT3 inhibition.
In epilepsy, genetic GLUT1 deficiency syndrome manifests in seizures starting from birth (Brockmann et al., 2001; Pearson et al., 2013) . In mice, GLUT3 deficiency has been shown to result in cognitive dysfunction and EEG seizures (16 times higher incidence than agematched controls, although mostly asymptomatic; Zhao et al., 2010) . At the same time, PTZ-and kainateinduced seizures have been reported to result in increased expression of both GLUT3 and GLUT1 (Gronlund et al., 1996) , supposedly to support increased energy demand by the hyperactive brain. Together with the observed hypometabolism during the "quiet" periods following seizures, the fact that in our experiments seizures resulted in reduced glucose uptake suggests that glucose transporter expression is not the culprit behind this abnormality. Interestingly, a medium-odd-chain triglyceride, triheptanoin (an anaplerotic mitochondrial fuel) has been proved to be efficient in treatment of GLUT1 deficiency syndrome as well as of amyotrophic lateral sclerosis, the long-chain fat oxidation disorders, and other human metabolic problems (Borges and Sonnewald, 2012; Roe and Brunengraber, 2015; Tefera et al., 2017) .
Furthermore, while GLUT3 is considered to be the major neuronal glucose transporter in the brain (Duelli and Kuschinsky, 2001) , it was shown that GLUT3 haploinsufficiency (50% reduction in expression) in mice brains did not lead to any observable difference in glucose uptake or utilization (Stuart et al., 2011) , suggesting that GLUT3 expression is more than abundant under normal conditions and should not be a limiting factor in pathological brain glucose uptake inhibition. Analysis of genetic mutations in genes encoding for GLUT3 or lactate transporters (MCTs) also found no mutations responsible for epilepsy (Hildebrand et al., 2014) .
While we cannot rule out the role of glucose transporters in neurodegenerative diseases' early pathogenesis, our results and somewhat contradictory available data from other studies suggest that the exact involvement of neuronal glucose transporters in pathological glucose uptake in neurodegenerative diseases remains elusive.
Neuronal Hyperactivity and Cognitive Impairment in AD
The question of principal importance is whether the prevention of neuronal hyperactivity, fundamental for epilepsy, is sufficient for halting the progress of cognitive impairment in AD. Remarkably positive effects of the antiepileptic drug levetiracetam on aberrant network activity and cognitive deficits in hAPP mice have been reported (Sanchez et al., 2012) , suggesting a causal link between network hyperactivity and subsequent cognitive impairment in AD. These levetiracetam effects (as well as another antiepileptic topiramate) were also later confirmed for APPswe/PS1dE9 transgenic mice (Shi et al., 2013) . Although both studies used the only cognitive test (Moris water maze), recent reports show the beneficial effect of pyruvate on cognition in 3xTg-AD mice (Isopi et al., 2014) and the rat sporadic AD model .
However, our preliminary studies showed that although the chronic pyruvate treatment revealed a trend towards cognitive improvement in APP/PS1 mice, it did not result in radical amelioration of cognitive deficits (Koivisto et al., 2016; Zilberter et al., 2015a) . Despite network hyperactivity being one of the earliest markers of AD (Busche and Konnerth, 2016) , exact further progression may depend on additional various comorbidities in such a multifaceted disease. In AD, one such major pathology is likely brain insulin resistance (Biessels and Reagan, 2015; De Felice et al., 2014; de la Monte and Tong, 2014; Xie et al., 2002) and oxidative stress (Abeti and Duchen 2012; Cervellati et al., 2016) , presumably directly induced by Ab. Therefore, we suggest that an effective AD treatment should combine simultaneous, multi-target compensation for AD-induced insulin resistance, energy deficiency, oxidative stress, and neuroinflammation.
CONCLUSION
The human brain is the most energy-consuming organ in our body. It is not surprising, therefore, that any disturbances in the brain energy supply would constitute a danger to its normal function. Indeed, as it turns out, brain hypometabolism is a major shared risk factor among most, if not all, neurodegenerative disorders, playing a major role in multiple feedback loops of disease progression. Recent data, including our own, put glucose metabolism deficiency front and centre among the initiating factors of sporadic AD, PD, and acquired epilepsy pathogenesis, suggesting that correcting this abnormality might prove to be a decisive and efficient treatment of neurodegenerative diseases. With current treatment options severely limited, such results give hope of a light at the end of the tunnel in our search for a cure.
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